<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427557</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0553</org_study_id>
    <nct_id>NCT00427557</nct_id>
  </id_info>
  <brief_title>Cellular Therapy With Cord Blood Cells</brief_title>
  <official_title>Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if giving umbilical cord blood along
      with standard stem cells after high-dose chemotherapy will improve the response to a stem
      cell transplant. The safety of this treatment will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cord blood is a source of blood-forming cells that can be used for transplantation. Cord
      blood cells are taken from the umbilical cords of women who have given birth, and who have
      volunteered to donate their umbilical cord. Researchers hope that using cord blood before a
      stem cell transplant will help to reduce the risk of graft-versus-host-disease (GVHD). GVHD
      occurs when donor cells attack the cells of the person receiving the transplant.

      If you are found to be eligible to take part in this study, you will receive chemotherapy for
      5 days. You will receive fludarabine over about 30 minutes through a needle in your vein on
      Days 1-4. You will receive melphalan through a needle in your vein over about 30 minutes on
      Day 5.

      On Day 7, you will receive the cord blood cells through a needle in your vein over about 30
      minutes.

      On Day 12, you will receive blood stem cells through a needle in your vein over 30-60
      minutes. The stem cells you receive will be from a stem cell donor whose human leukocyte
      antigen (HLA- proteins on cells) type matches yours.

      If appropriate for the disease, you will also receive rituximab about once weekly for 4
      weeks, beginning on the day you receive melphalan. Rituximab is given though a needle in your
      vein over 2-3 hours.

      You will receive the drugs tacrolimus and methotrexate to lower the risk of GVHD. Tacrolimus
      will be given through a needle in your vein non-stop for 2 weeks, starting 12 hours after the
      stem cell transplant. After the first 2 weeks, you will continue to receive tacrolimus by
      mouth, for at least 3 months. You will receive methotrexate though a needle in your vein over
      30 minutes, starting 1 day after the stem cell transplant, for a total of 3 doses over the
      first 6 days after the stem cell transplant.

      You will receive the G-CSF (granulocyte-colony stimulating factor) to help you blood cell
      counts recover. G-CSF will be given as an injection under the skin, beginning 1 week after
      the stem cell transplant. You will continue to receive G-CSF once a day until your blood cell
      counts reach a certain high enough level.

      You will need to stay in the hospital for about 4 weeks beginning on Day 1. While you are in
      the hospital, blood (about 2 teaspoons) will be drawn every day for routine tests.

      After you leave the hospital, you will return to the hospital for visits 2-3 times a week for
      at least 100 days after the transplant. During these visits, you will have a physical exam
      and blood (about 2 teaspoons) will be drawn for routine tests.

      You will be asked to come back to the clinic for follow-up visits at 3, 6, 9 and 12 months
      after your transplant for routine safety testing. This will include a physical exam, a bone
      marrow biopsy, and blood (about 2 teaspoons) will be drawn for routine testing.

      You will be considered off-study after the 12-month follow-up visit.

      This is an investigational study. The stem cell transplant, the umbilical cord transplant,
      and all drugs used on this study are FDA approved. The use of umbilical cord blood and stem
      cells together is investigational. Up to 30 patients will take part in this study. All will
      be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Engraftment</measure>
    <time_frame>Baseline to 100 days post-engraftment</time_frame>
    <description>Engraftment defined as first of three (3) consecutive days with Absolute neutrophil count (ANC) equal to or more than 0.5 * 10^9/L; assessed from baseline to 100 days post-engraftment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cellular Therapy with Cord Blood Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 30 mg/m^2 intravenous (IV) for 4 Days + Melphalan 140 mg/m^2 IV for 1 Day + Rituximab 375 mg/m^2 IV once weekly + Cord Blood Transplantation + Stem Cell Transplantation Infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m^2 by vein for 4 Days (Day -10 through Day -7).</description>
    <arm_group_label>Cellular Therapy with Cord Blood Cells</arm_group_label>
    <other_name>Fludara</other_name>
    <other_name>Fludarabine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>140 mg/m^2 by vein for 1 Day (Day -7).</description>
    <arm_group_label>Cellular Therapy with Cord Blood Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood</intervention_name>
    <description>1 UCB Unit by vein on Day -5.</description>
    <arm_group_label>Cellular Therapy with Cord Blood Cells</arm_group_label>
    <other_name>UCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).</description>
    <arm_group_label>Cellular Therapy with Cord Blood Cells</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Infusion</intervention_name>
    <description>Infusion of blood stem cells on Day 0.</description>
    <arm_group_label>Cellular Therapy with Cord Blood Cells</arm_group_label>
    <other_name>SCT</other_name>
    <other_name>Stem Cell Transplant</other_name>
    <other_name>Allogeneic Hematopoietic Stem Cell Transplantation</other_name>
    <other_name>AHSCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with multiple myeloma (MM), acute myeloid leukemia (AML), myelodysplastic
             syndrome (MDS), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL),
             Hodgkin's lymphoma (HL), or chronic lymphocytic leukemia (CLL) in greater than first
             complete remission who are candidates for a non-ablative or reduced intensity
             conditioning regimen.

          2. Age up to 80 years.

          3. A related or unrelated donor who is HLA-matched at HLA, A, B, C, DR and DQ loci is
             acceptable (i.e. 10/10 matched related or unrelated donor, matched with molecular
             high-resolution technique per current standard for the BMT program). Donor must be
             willing to donate peripheral blood or bone marrow progenitor cells.

          4. Available cord blood unit must contain a minimum of 1.5 * 10^7 total nucleated cells
             per kg, and be at least a 4/6 HLA match with patient.

          5. Zubrod PS less than or equal to 2 or Lansky PS greater than or equal to 50%.

          6. Left ventricular ejection fraction &gt;40%. No uncontrolled arrhythmias or symptomatic
             heart disease.

          7. Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC) and Diffusion
             Capacity (DLCO) &gt;40%.

          8. Serum creatinine &lt;2.0 mg/dL. Serum bilirubin &lt;3 * upper limit of normal, SGPT &lt;4 *
             upper limit of normal.

        Exclusion Criteria:

          1. Patients with active CNS disease

          2. Positive Beta HCG in a woman with child bearing potential defined as not
             post-menopausal for 12 months or no previous surgical sterilization.

          3. Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study, including but not limited to active uncontrolled infection,
             uncontrolled cardiac arrhythmia or ischemic event, or uncontrolled psychosis, major
             depression, or mania.

          4. Evidence of chronic, active hepatitis or cirrhosis, or HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Partow Kebriaei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>April 19, 2012</results_first_submitted>
  <results_first_submitted_qc>April 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 17, 2012</results_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Hodgkin's Lymphoma</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Cellular Therapy</keyword>
  <keyword>Umbilical Cord Blood Cells</keyword>
  <keyword>Cord Blood Transplantation</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Graft vs. Host Disease</keyword>
  <keyword>GVD</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Fludarabine Phosphate</keyword>
  <keyword>Fludara</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituxan</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: January 05, 2007 to November 05, 2010. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>One participant of the 31 was enrolled but did not receive treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cellular Therapy With Cord Blood Cells</title>
          <description>Fludarabine 30 mg/m^2 intravenous (IV) for 4 Days + Melphalan 140 mg/m^2 IV for 1 Day + Rituximab 375 mg/m^2 IV once weekly + Cord Blood Transplantation + Stem Cell Transplantation Infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cellular Therapy With Cord Blood Cells</title>
          <description>Fludarabine 30 mg/m^2 intravenous (IV) for 4 Days + Melphalan 140 mg/m^2 IV for 1 Day + Rituximab 375 mg/m^2 IV once weekly + Cord Blood Transplantation + Stem Cell Transplantation Infusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Engraftment</title>
        <description>Engraftment defined as first of three (3) consecutive days with Absolute neutrophil count (ANC) equal to or more than 0.5 * 10^9/L; assessed from baseline to 100 days post-engraftment.</description>
        <time_frame>Baseline to 100 days post-engraftment</time_frame>
        <population>Analysis per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine + Melphalan + Umbilical Cord Blood Unit</title>
            <description>Fludarabine 30 mg/m^2 given daily for four days. Melphalan 140 mg/m^2 given for one day. Umbilical Cord Blood Unit given on one day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Engraftment</title>
          <description>Engraftment defined as first of three (3) consecutive days with Absolute neutrophil count (ANC) equal to or more than 0.5 * 10^9/L; assessed from baseline to 100 days post-engraftment.</description>
          <population>Analysis per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 Years and 3 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cellular Therapy With Cord Blood Cells</title>
          <description>Fludarabine 30 mg/m^2 intravenous (IV) for 4 Days + Melphalan 140 mg/m^2 IV for 1 Day + Rituximab 375 mg/m^2 IV once weekly + Cord Blood Transplantation + Stem Cell Transplantation Infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Graft Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic Thrombocytopenia Purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hemolytic Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Low Blood Pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry Vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>GastrointestinaI Bleed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Graft vs Host Disease</sub_title>
                <counts group_id="E1" events="41" subjects_affected="22" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Delayed Engraftment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Liver Function Tests</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Veno Occulusive Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="45" subjects_affected="22" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diffuse Alveolar Hemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Partow Kebriaei</name_or_title>
      <organization>MD Anderson Cancer Center</organization>
      <phone>713-563-5174</phone>
      <email>celsaenz@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

